Frequency of Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) descriptors in the acutely ill SLE group stratified by outcome, disease flare or infection
| SELENA-SLEDAI descriptor* | Disease flare (n=11) | Infection (n=16) | p Value |
|---|---|---|---|
| Vasculitis | 9% (1) | 6% (1) | 0.782 |
| Arthritis | 9% (1) | 13% (2) | 0.782 |
| Urinary casts | 18% (2) | 6% (1) | 0.332 |
| Haematuria | 55% (6) | 19% (3) | 0.053 |
| Proteinuria | 55% (6) | 6% (1) | 0.005 |
| Pyuria | 36% (4) | 13% (2) | 0.143 |
| Rash | 36% (4) | 19% (3) | 0.305 |
| Alopecia | 9% (1) | 0 | 0.219 |
| Mucosal ulcers | 18% (2) | 6% (1) | 0.332 |
| Pleuritis | 18% (2) | 13% (2) | 0.683 |
| Pericarditis | 0 | 6% (1) | 0.52 |
| Fever | 55% (6) | 94% (15) | 0.016 |
| Platelets <100 000 | 9% (1) | 19% (3) | 0.488 |
| WBC<3000 | 18% (2) | 13% (2) | 0.683 |
| Mean SLEDAI±SD (range) | 13±6 (2–21) | 6.3±6.9 (0–24) | 0.016 |
Seizure, psychosis, organic brain syndrome, visual disturbance, cranial neuropathy, headache, cerebrovascular accidents and myositis did not occur in this cohort and are not represented in this table. Serologies are reported in table 1.
SLE, systemic lupus erythematosus; WBC, white blood cell.